NCT03269058View on ClinicalTrials.gov

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

May 6, 2021

Study Completion Date

May 6, 2021

Conditions
Type-2 DiabetesOral Antidiabetics
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10 mg daily per os

DRUG

Placebos

Placebo of Dapagliflozin per day per os

Trial Locations (2)

21079

CHU Dijon Bourgogne, Dijon

44093

CHU de Nantes, Nantes

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT03269058 - Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter